Literature DB >> 15180632

Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder.

J I Gillespie1.   

Abstract

OBJECTIVE: To explore the influence of intracellular cAMP on phasic activity in the isolated bladder (phasic rises in intravesical pressure associated with waves of contraction and local stretches that can be activated by muscarinic or nicotinic agonists), as it has been argued that this activity underlies nonmicturition contractions, and that it contributes to the generation and modulation of afferent nerve activity.
MATERIALS AND METHODS: Isolated whole bladders from female guinea pigs (270-300 g) were cannulated via the urethra and suspended in a chamber containing oxygenated Tyrode solution at 33-35 degrees C. Bladder pressure was recorded and pharmacological agents added to the solution bathing the abluminal surface of the bladder.
RESULTS: Forskolin (1-3 micro mol/L), an activator of adenyl cyclase, reduced the frequency and amplitude of the phasic activity induced by the muscarinic agonist arecaidine (300 nmol/L). There were similar changes in frequency and amplitude in bladders exposed to the nonspecific phosphodiesterase (PDE) inhibitor iso-butyl-methyl-xanthene (IBMX). The actions of specific PDE inhibitors were explored to assess which isoenzymes might be responsible for regulating phasic activity. ENHA (PDE-2), zaprinast (PDE-5, -6, -8, -9 and -11) and siguazodan (PDE-3) had no effect. Zardavarine (PDE-3, -4) and Ro 20-1724 (PDE-4) reduced both the frequency and amplitude of the phasic activity. Nerve-mediated rises in intravesical pressure were also inhibited by Ro 20-1724, and the inhibition was more pronounced at 6.5 Hz than at 30 Hz stimulation. Ro 20-1724 inhibited nerve-mediated fluctuations induced by prolonged (200 s) stimulation at 6.5 Hz.
CONCLUSION: The mechanisms influencing the frequency of agonist-induced phasic activity in the isolated bladder are slowed by cAMP. Degradation of intracellular cAMP in the cells responsible for phasic activity appears to involve primarily PDE-4. The importance of these observations in relation to the overall physiological regulation of the bladder are discussed, and the possible importance of these findings in the development of pharmacological strategies to modulated bladder activity reviewed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180632     DOI: 10.1111/j.1464-410X.2004.04840.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  12 in total

1.  Inhibition of vascular smooth muscle inward-rectifier K+ channels restores myogenic tone in mouse urinary bladder arterioles.

Authors:  Nathan R Tykocki; Adrian D Bonev; Thomas A Longden; Thomas J Heppner; Mark T Nelson
Journal:  Am J Physiol Renal Physiol       Date:  2017-02-01

Review 2.  Excitability and contractility in arterioles and venules from the urinary bladder.

Authors:  Nathan R Tykocki; Frederick C Monson
Journal:  Curr Top Membr       Date:  2020-02-17       Impact factor: 3.049

3.  Prospective pharmacologic therapies for the overactive bladder.

Authors:  Karl-Erik Andersson
Journal:  Ther Adv Urol       Date:  2009-06

4.  Inhibition of phosphodiesterases relaxes detrusor smooth muscle via activation of the large-conductance voltage- and Ca²⁺-activated K⁺ channel.

Authors:  Wenkuan Xin; Qiuping Cheng; Rupal P Soder; Georgi V Petkov
Journal:  Am J Physiol Cell Physiol       Date:  2012-02-08       Impact factor: 4.249

5.  Role of PTHrP in attenuating transient pressure rises and associated afferent nerve activity of the rat bladder.

Authors:  Ayu Sugiura; Retsu Mitsui; Hikaru Hashitani
Journal:  Pflugers Arch       Date:  2022-07-30       Impact factor: 4.458

Review 6.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 7.  Therapeutic receptor targets for lower urinary tract dysfunction.

Authors:  Naoki Yoshimura; Yasuhiro Kaiho; Minoru Miyazato; Takakazu Yunoki; Changfeng Tai; Michael B Chancellor; Pradeep Tyagi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-21       Impact factor: 3.000

Review 8.  Rationale for the use of prostaglandins and phosphodiesterase inhibitors in the treatment of functional bladder disorders.

Authors:  Mohammad Sajjad Rahnama'i; Gommert A Van Koeveringe; Philip E Van Kerrebroeck
Journal:  Nephrourol Mon       Date:  2013-11-13

9.  Transient contractions of urinary bladder smooth muscle are drivers of afferent nerve activity during filling.

Authors:  Thomas J Heppner; Nathan R Tykocki; David Hill-Eubanks; Mark T Nelson
Journal:  J Gen Physiol       Date:  2016-03-14       Impact factor: 4.086

10.  Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder.

Authors:  Weixiang He; Han Xiang; Daoquan Liu; Jianmin Liu; Mingzhou Li; Qian Wang; Qiaofeng Qian; Yan Li; Xun Fu; Ping Chen; Yuming Guo; Guang Zeng; Zhonghua Wu; Daxing Zhan; Xinghuan Wang; Michael E DiSanto; Xinhua Zhang
Journal:  J Cell Mol Med       Date:  2020-10-03       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.